Form 4: Theravance Biopharma Director Eli Samaha Acquires $999,800 in Common Stock

Director Eli Samaha reports purchasing $999,800 worth of Theravance Biopharma (TBPH) common stock on August 7, 2024.

Summary

• On August 7, 2024, Eli Samaha, a director of Theravance Biopharma, Inc. (TBPH), purchased 999,800 shares of common stock at a price of $7.8 per share.
• Following the transaction, Samaha indirectly owns 9,511,150 shares through funds managed by Madison Avenue Partners, LP, where he serves as the managing partner.
• Samaha disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: Insider buying is generally viewed as a positive sign, suggesting confidence in the company's future. However, the filing itself is a routine disclosure.

Positives

• A director's purchase of a significant amount of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (officers, directors, or those holding more than 10% of a company's shares) buy or sell their company's stock. These filings are closely watched by investors as they can provide insights into management's view of the company's prospects.

Stakeholder Impact

• The stock purchase by a director could positively influence shareholder sentiment.

Key Dates